Development and Validation of an Artificial Intelligence-Powered Platform for Prostate Cancer Grading and Quantification

被引:25
作者
Huang, Wei [1 ,2 ]
Randhawa, Ramandeep [2 ,3 ]
Jain, Parag [2 ]
Iczkowski, Kenneth A. [4 ]
Hu, Rong [1 ]
Hubbard, Samuel [1 ]
Eickhoff, Jens [5 ]
Basu, Hirak [6 ]
Roy, Rajat [2 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, 1111 Highland Ave, Madison, WI 53705 USA
[2] PathomIQ, Silicon Valley, CA USA
[3] Univ Southern Calif, Marshall Sch Business, Los Angeles, CA 90007 USA
[4] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[5] Univ Wisconsin, Dept Biostat & Informat, Madison, WI 53706 USA
[6] Univ Texas MD Anderson Canc Ctr, Univ Texas Hlth Sci Ctr Houston, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
关键词
ISUP CONSENSUS-CONFERENCE; INTEROBSERVER REPRODUCIBILITY; INTERNATIONAL SOCIETY; CLINICAL STAGE; BIOPSIES; CARCINOMA; DIAGNOSIS; ADENOCARCINOMA; UTILITY; UPDATE;
D O I
10.1001/jamanetworkopen.2021.32554
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The Gleason grading system has been the most reliable tool for the prognosis of prostate cancer since its development. However, its clinical application remains limited by interobserver variability in grading and quantification, which has negative consequences for risk assessment and clinical management of prostate cancer. OBJECTIVE To examine the impact of an artificial intelligence (AI)-assisted approach to prostate cancer grading and quantification. DESIGN, SETTING, AND PARTICIPANTS This diagnostic study was conducted at the University of Wisconsin-Madison from August 2, 2017, to December 30, 2019. The study chronologically selected 589 men with biopsy-confirmed prostate cancer who received care in the University of Wisconsin Health System between January 1, 2005, and February 28, 2017. A total of 1000 biopsy slides (1 or 2 slides per patient) were selected and scanned to create digital whole-slide images, which were used to develop and validate a deep convolutional neural network-based AI-powered platform. The whole-slide images were divided into a training set (n = 838) and validation set (n = 162). Three experienced academic urological pathologists (W.H., K.A.I., and R.H., hereinafter referred to as pathologists 1, 2, and 3, respectively) were involved in the validation. Data were collected between December 29, 2018, and December 20, 2019, and analyzed from January 4, 2020, to March 1, 2021. MAIN OUTCOMES AND MEASURES Accuracy of prostate cancer detection by the AI-powered platform and comparison of prostate cancer grading and quantification performed by the 3 pathologists using manual vs AI-assisted methods. RESULTS Among 589 men with biopsy slides, the mean (SD) age was 63.8 (8.2) years, the mean (SD) prebiopsy prostate-specific antigen level was 10.2 (16.2) ng/mL, and the mean (SD) total cancer volume was 15.4% (20.1%). The AI system was able to distinguish prostate cancer from benign prostatic epithelium and stroma with high accuracy at the patch-pixel level, with an area under the receiver operating characteristic curve of 0.92 (95% CI, 0.88-0.95). The AI system achieved almost perfect agreement with the training pathologist (pathologist 1) in detecting prostate cancer at the patch-pixel level (weighted kappa = 0.97; asymptotic 95% CI, 0.96-0.98) and in grading prostate cancer at the slide level (weighted kappa = 0.98; asymptotic 95% CI, 0.96-1.00). Use of the AI-assisted method was associated with significant improvements in the concordance of prostate cancer grading and quantification between the 3 pathologists (eg, pathologists 1 and 2: 90.1% agreement using AI-assisted method vs 84.0% agreement using manual method; P < .001) and significantly higher weighted kappa values for all pathologists (eg, pathologists 2 and 3: weighted kappa = 0.92 [asymptotic 95% CI, 0.90-0.94] for AI-assisted method vs 0.76 [asymptotic 95% CI, 0.71-0.80] for manual method; P < .001) compared with the manual method. CONCLUSIONS AND RELEVANCE In this diagnostic study, an AI-powered platform was able to detect, grade, and quantify prostate cancer with high accuracy and efficiency and was associated with significant reductions in interobserver variability. These results suggest that an AI-powered platform could potentially transform histopathological evaluation and improve risk stratification and clinical management of prostate cancer.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] A Validation Study Involving Development of Model by Application of Artificial Intelligence in Screening and Prognosis of Breast Cancer
    Unnisa, Aziz
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 426 - 434
  • [32] A Systematic Review of Artificial Intelligence in Prostate Cancer
    Van Booven, Derek J.
    Kuchakulla, Manish
    Pai, Raghav
    Frech, Fabio S.
    Ramasahayam, Reshna
    Reddy, Pritika
    Parmar, Madhumita
    Ramasamy, Ranjith
    Arora, Himanshu
    RESEARCH AND REPORTS IN UROLOGY, 2021, 13 : 31 - 39
  • [33] Artificial intelligence for prostate cancer histopathology diagnostics
    Sandoval, Victor
    Chuang, Zachary
    Power, Nicholas
    Chin, Joseph L. K.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2022, 16 (12): : 439 - 441
  • [34] Development of artificial intelligence for the detection and staging of esophageal cancer
    Tokai, Yoshitaka
    Yoshio, Toshiyuki
    Fujisaki, Junko
    ANNALS OF ESOPHAGUS, 2023, 6
  • [35] Artificial Intelligence-Enabled Prostate Cancer Diagnosis and Prognosis: Current State and Future Implications
    Satturwar, Swati
    Parwani, Anil V.
    ADVANCES IN ANATOMIC PATHOLOGY, 2024, 31 (02) : 136 - 144
  • [36] Artificial intelligence in prostate cancer: Definitions, current research, and future directions
    George, Rose S.
    Htoo, Arkar
    Cheng, Michael
    Masterson, Timothy M.
    Huang, Kun
    Adra, Nabil
    Kaimakliotis, Hristos Z.
    Akgul, Mahmut
    Cheng, Liang
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (06) : 262 - 270
  • [37] Development and validation of an explainable artificial intelligence-based decision-supporting tool for prostate biopsy
    Suh, Jungyo
    Yoo, Sangjun
    Park, Juhyun
    Cho, Sung Yong
    Cho, Min Chul
    Son, Hwancheol
    Jeong, Hyeon
    BJU INTERNATIONAL, 2020, 126 (06) : 694 - 703
  • [38] Exploring the Use of Artificial Intelligence in the Management of Prostate Cancer
    Chu, Timothy N. N.
    Wong, Elyssa Y. Y.
    Ma, Runzhuo
    Yang, Cherine H. H.
    Dalieh, Istabraq S.
    Hung, Andrew J. J.
    CURRENT UROLOGY REPORTS, 2023, 24 (05) : 231 - 240
  • [39] Artificial Intelligence for Clinical Diagnosis and Treatment of Prostate Cancer
    Rabaan, Ali A.
    Bakhrebah, Muhammed A.
    AlSaihati, Hajir
    Alhumaid, Saad
    Alsubki, Roua A.
    Turkistani, Safaa A.
    Al-Abdulhadi, Saleh
    Aldawood, Yahya
    Alsaleh, Abdulmonem A.
    Alhashem, Yousef N.
    Almatouq, Jenan A.
    Alqatari, Ahlam A.
    Alahmed, Hejji E.
    Sharbini, Dalal A.
    Alahmadi, Arwa F.
    Alsalman, Fatimah
    Alsayyah, Ahmed
    Al Mutair, Abbas
    CANCERS, 2022, 14 (22)
  • [40] Development and validation pathways of artificial intelligence tools evaluated in randomised clinical trials
    Siontis, George C. M.
    Sweda, Romy
    Noseworthy, Peter A.
    Friedman, Paul A.
    Siontis, Konstantinos C.
    Patel, Chirag J.
    BMJ HEALTH & CARE INFORMATICS, 2021, 28 (01)